LIGAND PHARMACEUTICALS (LGND) Stock Analyst Ratings
USA - NASDAQ:LGND - US53220K5048 - Common Stock
209.29 USD
+6.81 (+3.36%)
209.29 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 85% to LGND. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 186.79. This target is -10.75% below the current price.
LGND was analyzed by 13 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about LGND.
In the previous month the buy percentage consensus was at a similar level.
LGND was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-10 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-11-07 | Benchmark | Maintains | Buy -> Buy |
| 2025-11-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-03 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-09-03 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-09-02 | Benchmark | Maintains | Buy -> Buy |
| 2025-08-28 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-08 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-07-30 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-05-09 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-04-10 | Stifel | Initiate | Buy |
| 2024-12-23 | Benchmark | Reiterate | Buy -> Buy |
| 2024-12-16 | Barclays | Maintains | Overweight -> Overweight |
| 2024-12-11 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-12-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-12 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-11-08 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-11-08 | Benchmark | Maintains | Buy -> Buy |
| 2024-11-08 | Barclays | Maintains | Overweight -> Overweight |
| 2024-11-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-28 | Barclays | Maintains | Overweight -> Overweight |
| 2024-10-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-10-03 | Oppenheimer | Initiate | Outperform |
| 2024-08-12 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-08-12 | Benchmark | Maintains | Buy -> Buy |
| 2024-08-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-07 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-07-30 | RBC Capital | Initiate | Outperform |
| 2024-07-09 | Craig-Hallum | Maintains | Buy -> Buy |
LIGAND PHARMACEUTICALS / LGND FAQ
What is the average price target for LIGAND PHARMACEUTICALS (LGND) stock?
13 analysts have analysed LGND and the average price target is 186.79 USD. This implies a price decrease of -10.75% is expected in the next year compared to the current price of 209.29.
How do analysts rate LIGAND PHARMACEUTICALS (LGND)?
The consensus rating for LIGAND PHARMACEUTICALS (LGND) is 84.6154 / 100 . This indicates that analysts generally have a positive outlook on the stock.